Skip to main content

Table 1 Patient characteristics

From: Exosome-based detection of EGFR T790M in plasma and pleural fluid of prospectively enrolled non-small cell lung cancer patients after first-line tyrosine kinase inhibitor therapy

Clinical characteristics Total 64 patients, n (%)
Age, median (range), years 66 (40–85)
Sex
 Female 47 (73.4)
 Male 17 (26.6)
Histologic type
 Adenocarcinoma 62 (96.9)
 Squamous cell carcinoma 2 (3.1)
Tumor stage
 IIa 1 (1.9)
 IIIb 1 (1.9)
 IVa 36 (66.7)
 IVb 26 (48.1)
M categorya
 M0 2 (3.1)
 M1a 24 (37.5)
 M1b 15 (23.4)
 M1c 23 (35.9)
Tissue EGFR genotypingb
 T790M and exon 19 deletionc 2 (3.1)
 Exon 19 deletion 33 (51.6)
 L858R 23 (35.9)
 Otherd 6 (9.4)
Prior treatment
 Gefitinib 34 (53.1)
 Erlotinib 11 (17.2)
 Afatinib 16 (25.0)
 Afatinib + Gefitinib 2 (3.1)
 Erlotinib + Gefitinib 1 (1.6)
  1. aAccording to the 8th TMN edition, M1a indicates lung metastases or pleural/pericardial malignant effusion or nodules; M1b indicates a single metastatic lesion in a single distant organ; M1c indicates multiple lesions in a single organ or multiple lesions in multiple organs
  2. bTissue genotyping was performed using the PANAMutyper EGFR kit (PANAGENE Inc., Daejeon, Korea)
  3. cTwo patients had T790M mutations that were identified though re-biopsy after EGFR-TKI therapy
  4. dOne exon 20 insertion, one L861Q, one G719X and S768I, and three patients with no tissue genotyping result
  5. Other not otherwise specified, TKI tyrosine kinase inhibitor